Exosomes Stand Out as Potential Blood Biomarkers
Could exosomes—tiny parcels extruded from cells—make for a blood-based Alzheimer’s marker?
588 RESULTS
Sort By:
Could exosomes—tiny parcels extruded from cells—make for a blood-based Alzheimer’s marker?
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
An amplification-based test picks up minute amounts of prion protein in the blood of asymptomatic carriers, but researchers wonder whether regulators will want to screen the population.
While scientists remain on the fence over whether computer games benefit cognition, some are finding new uses for gaming data in clinical trial research.
Brain-training websites tout their games’ potential to boost cognition, but strong evidence and firm backing by the scientific community have yet to surface.
Big-data project takes on Alzheimer's with a biomarker computational challenge.
A candidate reference method for measuring Aβ42 in cerebrospinal fluid brings researchers closer to standardization.
Will an antibody signature make for a new Alzheimer’s diagnostic?
European and U.S. agencies approve a third amyloid PET tracer, florbetaben.
A small longitudinal study suggests that atrophy begins in the frontoparietal cortex, not the hippocampus, in early Alzheimer's.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
A new test claims to detect Aβ oligomers in cerebrospinal fluid by exploiting their tendency to seed aggregation.